← All Sanofi filings

Sanofi 13F institutional holdings

Quarterly disclosures of US equity positions held by institutional managers with over $100 million under management.

NASDAQ
SNY
Sanofi
13F-HR: Sanofi 13F Holdings — June 30, 2026
Sanofi reported 10 holdings worth $534.0M for the period ended June 30, 2026.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Discloses Major Holdings in Biotech Firms
Sanofi's latest SEC filing reveals significant investments in several biotechnology companies, including Inhibrx Biosciences and MeiraGTx Holdings.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Discloses Q4 2025 Equity Holdings in Biotech Firms
Sanofi's latest 13F filing reveals its equity positions in eight biotechnology and pharmaceutical companies as of December 31, 2025, totaling over $310 million.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Discloses Q3 2025 Equity Portfolio Holdings
Sanofi's latest 13F filing reveals its public equity holdings as of September 30, 2025, totaling over $260 million across nine biotechnology and pharmaceutical companies.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Discloses Q2 2025 Equity Holdings in Latest 13F Filing
Sanofi's latest 13F filing reveals its equity portfolio as of June 30, 2025, totaling over $175 million across ten distinct holdings.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Reveals Q1 2025 Equity Portfolio: Significant Stakes in Biotech Firms
Sanofi's latest 13F filing unveils substantial holdings in several biotech companies, reflecting its investment strategy in the sector.
NASDAQ
SNY
Sanofi
13F-HR: Sanofi Discloses Q4 2024 Equity Portfolio: Significant Holdings in Biotech Firms
Sanofi's latest 13F filing reveals substantial investments in several biotechnology companies, including MeiraGTx Holdings plc and Novavax.